Disease phenotype and diagnostic delay in Saudi patients with primary Sjögren’s syndrome

Omair, Mohammed A.; Alqahtani, Bashaer; Alhamad, Esam H.; Tashkandy, Yusra; Othman, Nashwa; Al-Shahrani, Khalid A; Paramasivam, Muthurajan P.; Alenzi, Fahidah; Halwani, Rabih; Daghestani, Maha H.

doi:10.15537/smj.2021.42.4.20200767

Cited by 3 publications

(3 citation statements)

References 21 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prevalence of ILD in SSc ranged from 26.1% (Australia, 2015) 36 to 88.1% (India, 2013). 44 Similarly, Sjogren’s ILD ranged from 1% (Sweden, 2011) 55 to 87.8% (Saudi Arabia, 2021). 56 In addition to dissimilarities in the prevalence across various regions, we also observed variation within region-specific estimates.…”

Section: Resultsmentioning

confidence: 99%

Incidence and prevalence of interstitial lung diseases worldwide: a systematic literature review

et al. 2023

View full text Add to dashboard Cite

Interstitial lung disease (ILD) is a collective term representing a diverse group of pulmonary fibrotic and inflammatory conditions. Due to the diversity of ILD conditions, paucity of guidance and updates to diagnostic criteria over time, it has been challenging to precisely determine ILD incidence and prevalence. This systematic review provides a synthesis of published data at a global level and highlights gaps in the current knowledge base. Medline and Embase databases were searched systematically for studies reporting incidence and prevalence of various ILDs. Randomised controlled trials, case reports and conference abstracts were excluded. 80 studies were included, the most described subgroup was autoimmune-related ILD, and the most studied conditions were rheumatoid arthritis (RA)-associated ILD, systemic sclerosis associated (SSc) ILD and idiopathic pulmonary fibrosis (IPF). The prevalence of IPF was mostly established using healthcare datasets, whereas the prevalence of autoimmune ILD tended to be reported in smaller autoimmune cohorts. The prevalence of IPF ranged from 7 to 1650 per 100 000 persons. Prevalence of SSc ILD and RA ILD ranged from 26.1% to 88.1% and 0.6% to 63.7%, respectively. Significant heterogeneity was observed in the reported incidence of various ILD subtypes. This review demonstrates the challenges in establishing trends over time across regions and highlights a need to standardise ILD diagnostic criteria.PROSPERO registration number: CRD42020203035.

show abstract

Section: Resultsmentioning

confidence: 99%

Incidence and prevalence of interstitial lung diseases worldwide: a systematic literature review

et al. 2023

View full text Add to dashboard Cite

show abstract

“…According to a review conducted on 41 patients in Saudi Arabia, Interstitial lung disease and arthritis were the most common extra-glandular manifestations (EGM) affecting 27 (65.9%) patients for both. [7] We are revealing a primary SS case presented with myositis, arthritis, and ILD. [4] Although pulmonary lesions are not rare in primary SS, they oftentimes get condoned.…”

Section: Discussionmentioning

confidence: 99%

Myositis and Interstitial Lung Disease as a Presentation of Primary Sjogren’s Syndrome, A Case Report

Aly,

Mahmoud,

Hassan

et al. 2024

Preprint

View full text Add to dashboard Cite

Primary Sjogren's syndrome (SS), defined as an autoimmune disorder, is the most prevalent autoimmune disorder, succeeding rheumatoid arthritis, but persists undiagnosed in more than half of cases. The distinctive attribute of histopathological characteristics of SS is peri-epithelial lymphocytic infiltration of the impacted organs. Antibodies to SSA (Ro) and SSB (La) are characteristically correlated with SS. Pulmonary involvement in primary SS has been reported in multiple cases of Sjogren syndrome, with a range that includes various forms, starting from small airway diseases to interstitial lung diseases (ILD). We are reporting a primary SS case presenting with myositis and ILD.

show abstract

“…This study is part of a larger clinical study of patients with pSS in Saudi Arabia [19,20]. This study had a cross-sectional design and was performed between October 2018 and May 2019, with 117 Saudi male and female volunteers in total who were aged 18-77 years.…”

Section: Patient Populationmentioning

confidence: 99%

Association of Inflammatory Cytokine Levels with Extra Glandular Manifestations, Fatigue, and Disease Activity in Primary Sjögren’s Syndrome in Saudi Patients: A Cross-Sectional Study

Alqahtani,

Daghestani,

Omair

et al. 2023

Diagnostics

Self Cite

View full text Add to dashboard Cite

Background: Primary Sjögren’s syndrome (pSS) is an autoimmune disease that can cause fatigue and extraglandular manifestations (EGMs). pSS is associated with cytokine network dysregulation, which may be related to the immune-mediated destruction of exocrine glands. Objective: We determined cytokine levels and their relationship to EGMs, the European League Against Rheumatism (EULAR) Sjögren’s syndrome disease activity index (ESSDAI), and fatigue in Saudi patients with pSS. Methods: This study was a cross-sectional, single-center study. We included forty-one patients and 71 controls. Serum samples were collected from random healthy people and pSS patients who were followed in the rheumatology and pulmonary clinics of King Saud University Medical City in Riyadh, Saudi Arabia. Levels of the frequently studied cytokines were measured using Luminex xMAP technology. Each ESSDAI score and EGM were recorded, and the Arabic version of the fatigue severity scale (FSS) was applied to assess fatigue. The main outcome measures were cytokine levels in pSS Saudi patients using/not using immune-suppressive medications (ISMs). Results: Thirty-six (87.8%) patients had one or more EGMs, and the mean ESSDAI score was 9.95 ± 7.73. There was a significant decrease in TNFα and IL-21 levels in the pSS group compared to those in the control group (p = 0.034 and p < 0.001, respectively), whereas IL-12 levels were significantly elevated in the pSS group (p = 0.002). Cytokine levels in patients who used ISMs were the same as those in patients who did not use medications. Decreased IL-1β (p = 0.014), IL-2 (p = 0.035), IL-6 (p = 0.014), and IL-35 (p = 0.010) levels were observed in patients who had EGMs. Patients who had low disease activity exhibited low IL-10 (p = 0.018) and high IFN-α (p = 0.049), IFN-β (p = 0.049), IL-1β (p = 0.006), and IL-35 (p = 0.032) levels compared to patients with high disease activity. A negative association between a positive fatigue score and IL-1β (p = 0.010), IL-2 (p = 0.037), IFN-α (p = 0.025), TNFα (p = 0.030), IL-17 (p = 0.029), IL-12 (p = 0.046), and IL-21 (p = 0.005) levels was found. Conclusions: Cytokine profiles correlate with EGMs, ESSDAI, and fatigue. Patients with controlled disease activity have a normal cytokine profile that is similar to that of controls.

show abstract

Disease phenotype and diagnostic delay in Saudi patients with primary Sjögren’s syndrome

Cited by 3 publications

References 21 publications

Incidence and prevalence of interstitial lung diseases worldwide: a systematic literature review

Incidence and prevalence of interstitial lung diseases worldwide: a systematic literature review

Myositis and Interstitial Lung Disease as a Presentation of Primary Sjogren’s Syndrome, A Case Report

Association of Inflammatory Cytokine Levels with Extra Glandular Manifestations, Fatigue, and Disease Activity in Primary Sjögren’s Syndrome in Saudi Patients: A Cross-Sectional Study

Contact Info

Product

Resources

About